R406

For research use only. Not for use in humans.

目录号：S2194

CAS No. 841290-81-1

R406 是一种有效的 Syk 抑制剂，无细胞试验中IC50为41 nM，对Syk抑制作用强，但是不抑制Lyn，对Flt3的作用比对Syk低5倍。R406 可诱导凋亡。Phase 1。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2341.19	现货
5mg	RMB 1421.87	现货
50mg	RMB 7119.85	现货
200mg	RMB 16298.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的R406发表文献76篇：

Cancer Cell, 2021, S1535-6108(21)00492-X

PubMed: 34624218 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cancer Cell, 2017, 31(4):549-562

PubMed: 28399410 ( click the link to review the publication )

Nat Med, 2016, 22(8):915-23

PubMed: 27428901 ( click the link to review the publication )

Sci Transl Med, 2021, 13(596)eabf8654

PubMed: 33979301 ( click the link to review the publication )

Cell Rep, 2021, 36(6):109525

PubMed: 34380042 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Elife, 2021, 10e65962

PubMed: 33890572 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

Transl Res, 2021, 227:53-63

PubMed: 32687976 ( click the link to review the publication )

J Leukoc Biol, 2021, 10.1002/JLB.2A0520-334R

PubMed: 33884657 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2021, 320(5):C902-C915

PubMed: 33689480 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00238-6

PubMed: 33639170 ( click the link to review the publication )

iScience, 2021, 24(8):102871

PubMed: 34386732 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):956

PubMed: 33159047 ( click the link to review the publication )

Front Immunol, 2020, 11:610523

PubMed: 33552071 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Biomolecules, 2020, 10(9)E1283

PubMed: 32899943 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(19)E7009

PubMed: 32977621 ( click the link to review the publication )

ScholarsArchive@OSU, 2020, 51

PubMed: N/A ( click the link to review the publication )

ScholarsArchive@OSU, 2020, None

PubMed: None ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):203-213

PubMed: 30664786 ( click the link to review the publication )

mBio, 2019, 10(3)e00574-19

PubMed: 31064828 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007923

PubMed: 31449558 ( click the link to review the publication )
Cell Death Dis, 2019, 10(8):555

PubMed: 31324751 ( click the link to review the publication )

Front Immunol, 2019, 10:921

PubMed: 31139177 ( click the link to review the publication )

J Immunol, 2019, 203(12):3225-3236

PubMed: 31704879 ( click the link to review the publication )

Molecules, 2019, 24(20)E3640

PubMed: 31600968 ( click the link to review the publication )

PLoS One, 2019, 14(1):e0210879

PubMed: 30668583 ( click the link to review the publication )

Mucosal Immunol, 2019, 12(2):425-433

PubMed: 30664707 ( click the link to review the publication )

J Control Release, 2018, 288:227-238

PubMed: 30219279 ( click the link to review the publication )

J Bone Miner Res, 2018, 33(1):167-181

PubMed: 28914985 ( click the link to review the publication )

Front Immunol, 2018, 9:37

PubMed: 29410669 ( click the link to review the publication )

J Mol Cell Cardiol, 2018, 115:82-93

PubMed: 29274344 ( click the link to review the publication )

Cell Microbiol, 2018, 20(2)

PubMed: 29125705 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(2):127-136

PubMed: 29156121 ( click the link to review the publication )

Leukemia, 2017, 31(8):1686-1694

PubMed: 27890932 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1818-1830

PubMed: 28130226 ( click the link to review the publication )

EMBO Rep, 2017, 18(9):1604-1617

PubMed: 28705801 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2586-2597

PubMed: 28835384 ( click the link to review the publication )

J Immunol, 2017, 198(8):3181-3194

PubMed: 28264968 ( click the link to review the publication )

Sci Rep, 2017, 7:46064

PubMed: 28393919 ( click the link to review the publication )

PLoS Comput Biol, 2017, 13(3):e1005432

PubMed: 28306714 ( click the link to review the publication )

Oncotarget, 2017, 8(7):10931-10944

PubMed: 28077790 ( click the link to review the publication )

Clin Immunol, 2017, 175:69-74

PubMed: 27919819 ( click the link to review the publication )

Blood, 2017, 129(6):759-770

PubMed: 28011673 ( click the link to review the publication )

Blood, 2016, 127(25):3192-201

PubMed: 27095788 ( click the link to review the publication )

Leukemia, 2016, 30(5):1116-25

PubMed: 26867669 ( click the link to review the publication )
Cancer Res, 2016, 76(23):6937-6949

PubMed: 27758892 ( click the link to review the publication )

Cell Death Differ, 2016, 23(4):628-39

PubMed: 26450454 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(1):192-201

PubMed: 26763439 ( click the link to review the publication )

PLoS Pathog, 2016, 12(3):e1005487

PubMed: 26943817 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164895

PubMed: 27768734 ( click the link to review the publication )

J Allergy Clin Immunol, 2016, 138(3):839-851

PubMed: 27056269 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):57-67

PubMed: 25487280 ( click the link to review the publication )

Blood, 2015, 126(16):1911-20

PubMed: 26272216 ( click the link to review the publication )

Leukemia, 2015, 29(6):1350-9

PubMed: 25482129 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(1):789

PubMed: 25699542 ( click the link to review the publication )

J Leukoc Biol, 2015, 10.1189/jlb.3HI0814-371RR

PubMed: 25605870 ( click the link to review the publication )

Sci Rep, 2015, 5:16995

PubMed: 26592927 ( click the link to review the publication )

J Biomol Screen, 2015, 10.1177/1087057115585724

PubMed: 25948491 ( click the link to review the publication )

Immunity, 2014, 40(3):389-99

PubMed: 24631154 ( click the link to review the publication )

Blood, 2014, 124(4):590-7

PubMed: 24948657 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Nat Commun, 2014, 5:5444

PubMed: 25392121 ( click the link to review the publication )

J Bone Miner Res, 2014, 29(12):2618-35

PubMed: 24916406 ( click the link to review the publication )

Eur J Med Chem, 2014, 86C:664-675

PubMed: 25222877 ( click the link to review the publication )

Eur J Immunol, 2014, 44(12):3729-40

PubMed: 25251945 ( click the link to review the publication )

Exp Cell Res, 2014, 322(1):99-107

PubMed: 24406398 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96703

PubMed: 24846290 ( click the link to review the publication )

Exp Dermatol, 2014, 23(12):884-9

PubMed: 25267545 ( click the link to review the publication )
Blood, 2013, 122(4):580-9

PubMed: 23699602 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(3):586-97

PubMed: 23231952 ( click the link to review the publication )

Br J Haematol, 2013, 163(5):590-602

PubMed: 24117128 ( click the link to review the publication )

UVIC, 2013, Meritxell Aguiló García

PubMed: ( click the link to review the publication )

产品安全说明书

Syk抑制剂选择性比较

生物活性

产品描述

R406 是一种有效的 Syk 抑制剂，无细胞试验中IC50为41 nM，对Syk抑制作用强，但是不抑制Lyn，对Flt3的作用比对Syk低5倍。R406 可诱导凋亡。Phase 1。

特性

Rigel选择R406作为治疗风湿性关节炎的潜在领先药物。

靶点

Flt3 ^[1] (Cell-free assay)	Syk ^[1] (Cell-free assay)
	41 nM

体外研究

R406强抑制免疫球蛋白 E (IgE)和 IgG调节的受体信号活性。R406抑制IgE抗体诱导的 LTC4 ，细胞因子和趋化因子的产生和释放, 包括TNFα, IL-8, 和GM-CSF。R406 抑制肥大细胞中T细胞Syk底物链接蛋白的激活和B细胞中B细胞链接蛋白/SLP65的磷酸化作用。R406 结合到Syk的ATP结合袋中，抑制Syk的激酶活性， R406是ATP竞争性抑制剂，K_i为30 nM。R406阻断单核细胞/巨噬细胞和中性白细胞中Syk依赖的FcR调节活性，且阻断B淋巴细胞中BCR调节活性。^[1]406 明显诱导慢性淋巴细胞白血病（CCL）细胞凋亡，且阻断CCL3和CCL4 分泌。^[2] R406有效抑制血小板信号，且抑制使用特殊抗体或 HIT 病患的血浆通过FcγRIIA 交叉结合形成的功能。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
AMO-1	MmnnSpVv[3Srb36gRZN{[Xl?	M1;rOVEh\|ryP	M1HIU\|PDqGh?		MoT4doVlfWOnczDtbYdz[XSrb39CpC=>	NH\RfWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1NVc3OSd-Mk[yOVE4PjF:L3G+
U266	MVLGeY5kfGmxbjDBd5NigQ>?	MkHrNUDPxE1?	NG\tW5A{yqCq		NX20OIt5emWmdXPld{BucWe{YYTpc47DqA>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3MUe2NUc,OjZ{NUG3OlE9N2F-
Jeko-1	M4r0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkThOFghcA>?		NYe0VnBvUUN3ME21MlA3QDJ4IN88US=>	NWrheIQ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|U4PTVpPkK1PFM2PzV3PD;hQi=>
Mino	M1XsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHXKN281QCCq		M2\EeGlEPTB;NT63NFg2PCEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUe1OUc,OjV6M{W3OVU9N2F-
Jeko-1	MmrxRZBweHSxc3nzJGF{e2G7	NEjMems2yqEQvF2=	NWXCWJVROjRiaB?=		MWnpcoR2[2W\|IEK1MlHDqMLzwrCzMlLDqCViYYDvdJRwe2m\|	NEPjd2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVc2PSd-MkW4N\|U4PTV:L3G+
primary MCL	NEL3PIpCeG:ydH;zbZMhSXO\|YYm=	NU\sW\|RJOiEEtV2=	MYGyOEBp		MV7pcoNz\WG\|ZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXQEoB?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN6OEO3N{c,OjV\|OEizO\|M9N2F-
PBMCs	MoDzR4VtdCCYaXHibYxqfHliQYPzZZk>	NXfr[IdZOC13MDFOwG0>	NVnDN5h6OjRiaB?=	NYLKSXc6TE2VTx?=	MnfrbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{N{i2Nkc,OjVzMke4OlI9N2F-
PBMCs	MkHCSpVv[3Srb36gRZN{[Xl?	M1nuUlUh\|ryP	Ml;hNUBp	MWrEUXNQ	MV7k[YNz\WG\|ZYOgeIhmKGOnbHygcYloemG2aX;u	M{fYd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK3PFYzLz5{NUGyO\|g3OjxxYU6=
CFSE-CD4+ T	M4G0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3ve4QxNjB4MkWtNUDPxE1?	Mm\DOEBl		M1\Q[IJtd2OtczDwdo9tcW[ncnH0bY9vKG:oIFfWTGQu\GW{aY\l[EBETDRtwrDUJINmdGy\|IHHu[EBETDFzYjxCpINmdGy\|	M2\pbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nke5PVgzLz5{NE[3PVk5OjxxYU6=
CFSE-CD11b+	M2nFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnrNE4xPjJ3LUGg{txO	M4DWVVgh\A>?		NVHyNldu[myxY3vzJJBzd2yrZnXyZZRqd25ib3[gS3ZJTC2mZYLpeoVlKEOGNDxCpHQh[2WubIOgZY5lKEOGMUHiL:Kh[2WubIO=	NGnkc\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[3PVk5Oid-MkS2O\|k6QDJ:L3G+
HMECs	MYTGeY5kfGmxbjDBd5NigQ>?	NWG0fHo4OC1zMDFOwG0>	NFXke2wzOCCvaX6=		NWHCNFBmcW6qaXLpeJMhXkWJRj3zeIlufWyjdHXkJJJmdGWjc3Wgc4YhVk9?	M4jBZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K5OVQ1Lz5{NEOyPVU1PDxxYU6=
AB5	MWHBdI9xfG:\|aYOgRZN{[Xl?	MWqwMVIvPSEQvF2=	NXXISok1PDhiaB?=	MmPuSG1UVw>?	Mk\GbY5lfWOnczDhdI9xfG:\|aYO=	NUPiPI1qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVg6OTFpPkKzN\|k5QTFzPD;hQi=>
JB7	Ml\GRZBweHSxc3nzJGF{e2G7	NGLLN\|kxNTJwNTFOwG0>	MUi0PEBp	M4[0OmROW09?	NXHwOIx[cW6mdXPld{BieG:ydH;zbZM>	NY\PNndTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVg6OTFpPkKzN\|k5QTFzPD;hQi=>
AB5	NUHwOIpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX2wMVIvPSEQvF2=	Mmn4OFghcA>?	NGHLWpBFVVOR	MmXKbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dB?=	M4\OSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{m4PVEyLz5{M{O5PFkyOTxxYU6=
JB7	MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XwcVAuOi53IN88US=>	NWDPS\|FCPDhiaB?=	MYDEUXNQ	NUnnNGdJcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN7OEmxNUc,OjN\|OUi5NVE9N2F-
RL	M4\QfGZ2dmO2aX;uJGF{e2G7	NH74UnIzNjVxNTFOwG0>	NVLh[VV1OjRxNEigbC=>	M{fDdGROW09?	MUDpcoR2[2W\|IHGgdI91\W62IHTlZ5Jm[XOnIHnuJG1OWC17IH3SUmEh\XiycnXzd4lwdg>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{Nkm2OUc,OjF7Mk[5OlU9N2F-
RL	MlvjSpVv[3Srb36gRZN{[Xl?	MlzoNU8zNjVizszN	MYOyOEBp	NX3DN4J3TE2VTx?=	NUTpVYJxemWmdXPld{B1cGViYXP0bZZifGmxbjDv[kBCc3RiYX7kJJA4OFN4Sx?=	NFTNRZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmyOlk3PSd-MkG5NlY6PjV:L3G+
platelet	MoGxSpVv[3Srb36gRZN{[Xl?	MnHxNeKh\|ryv	MnfmOUBucW5?		MmH2bY5pcWKrdIOgSoPPu1KLSVGtcYVlcWG2ZXSgdIxifGWuZYSgZYdoemWpYYTpc44>	NHPvSms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi0PFY6PCd-MkG4OFg3QTR:L3G+
platelet	NHTWUnFHfW6ldHnvckBCe3OjeR?=	M2ftXFAvODVxMT:yMlUh\|ryP	M1zmSVUhdWmw		MXXpcohq[mm2czD0bIUhe2mpbnHsbY5oKG2nY3jhcol{dXNiZH;3cpN1emWjbTDv[kBH[87\|UlnJRS=>	NXjOO21GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OFg3QTRpPkKxPFQ5Pjl2PD;hQi=>
DoHH2	M4\kPWFxd3C2b4Ppd{BCe3OjeR?=	NUTjbVZ4OC9\|L{GwJO69VQ>?	MVq0PEBp		NGnHW4NqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueR?=	M3XtRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEe1OFA5Lz5{MEi3OVQxQDxxYU6=
Jeko-1	M4rmOGFxd3C2b4Ppd{BCe3OjeR?=	NF7PNlcxNzNxMUCg{txO	M4TPZVQ5KGh?		NF7nU3BqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueR?=	NX;DTG1mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O\|U1ODhpPkKwPFc2PDB6PD;hQi=>
Raji	NEf3WlRCeG:ydH;zbZMhSXO\|YYm=	NWr6[oJjOC9\|L{GwJO69VQ>?	MUm0PEBp		NFyxOZBqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueR?=	NWKyb3gxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O\|U1ODhpPkKwPFc2PDB6PD;hQi=>
DHL4	MVrBdI9xfG:\|aYOgRZN{[Xl?	M17G[VAwOS92IN88US=>	M4TzXFk3KGh?		NVzNXoRqcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	M3LhTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
LY7	NXnNemhqSXCxcITvd4l{KEG\|c3H5	M{PHblAwOS92IN88US=>	MnzOPVYhcA>?		MojPbY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY3	NHPMO2pCeG:ydH;zbZMhSXO\|YYm=	NXTFWY02OC9zL{Sg{txO	M3TwZlk3KGh?		MYTpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NEjBUJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
DHL6	NUDGO5B1SXCxcITvd4l{KEG\|c3H5	NXrudYc6OC9zL{Sg{txO	NF3aO\|c6PiCq		NYj1R3ZpcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	MorZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY10	Ml\oRZBweHSxc3nzJGF{e2G7	MkXaNE8yNzRizszN	MmTxPVYhcA>?		NY\yOoNDcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	M2XNPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL10	NF7wc\|BCeG:ydH;zbZMhSXO\|YYm=	MnzJNE8yNzRizszN	M1vxR\|k3KGh?		NYe3[YptcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	NIXwS5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
Wsu-NHL	MVXBdI9xfG:\|aYOgRZN{[Xl?	NYWz[WFWOC9zL{Sg{txO	MnvQPVYhcA>?		MUPpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NXXRWHh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
LY18	M4jEOGFxd3C2b4Ppd{BCe3OjeR?=	MU[wM\|EwPCEQvF2=	NGrIZoo6PiCq		MlH1bY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	MnXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY1	MmLHRZBweHSxc3nzJGF{e2G7	MkTaNE8yNzRizszN	NWXwUYF6QTZiaB?=		NH7UcYpqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	MlzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
DHL8	M1fySGFxd3C2b4Ppd{BCe3OjeR?=	M4L3TlAwOS92IN88US=>	MV:5OkBp		Mo[xbY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	NIrKe5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
DHL4	NIHm[nJCeG:ydH;zbZMhSXO\|YYm=	M4DwVlQh\|ryP	MYC5OkBp		Ml\ibY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{A6KGGwZDCzMEBjfXRibn;0JINie3Cjc3WgPC=>	MlTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
DHL6	M4DvcmFxd3C2b4Ppd{BCe3OjeR?=	NUTkWJF{PCEQvF2=	NVL4SnZ[QTZiaB?=		NYPqfZIzcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmeyB7IHHu[EA{NCCkdYSgco91KGOjc4Dhd4UhQA>?	MmTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY3	NHnWSY9CeG:ydH;zbZMhSXO\|YYm=	MUi0JO69VQ>?	MWG5OkBp		NImwclZqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{KDliYX7kJFMtKGK3dDDuc5Qh[2G\|cHHz[UA5	MmTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY7	MV7BdI9xfG:\|aYOgRZN{[Xl?	MVW0JO69VQ>?	MlfhPVYhcA>?		NW\nXW9pcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmeyB7IHHu[EA{NCCkdYSgco91KGOjc4Dhd4UhQA>?	M1eyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL4	M2LkS2Z2dmO2aX;uJGF{e2G7	M1LMblQh\|ryP	Mkj6NVYhcA>?		NUPXNINqcW6qaXLpeJMhfG:waXOgRmxPUyC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44>	Mle1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY7	M4XE[GZ2dmO2aX;uJGF{e2G7	M2rxVVQh\|ryP	NWq1eW95OTZiaB?=		NIjxU2FqdmirYnn0d{B1d26rYzDCUG5MKHS7cn;zbY5mKHCqb4PwbI9zgWyjdHnvci=>	NHuxUmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECwOlY6Pid-MUiwNFY3QTZ:L3G+
LY3	NWLE[mdETnWwY4Tpc44hSXO\|YYm=	MlnWOEDPxE1?	M1nwW\|E3KGh?		MlPWbY5pcWKrdIOgeI9vcWNiQlzOT{B1gXKxc3nu[UBxcG:\|cHjvdplt[XSrb36=	M1qyR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEC2Olk3Lz5zOECwOlY6PjxxYU6=
DHL6	NFr3TWJHfW6ldHnvckBCe3OjeR?=	M1TkSVQh\|ryP	MUOxOkBp		M4XQXYlvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u	MnTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
LY10	NVjCfpJJTnWwY4Tpc44hSXO\|YYm=	M1LkfVQh\|ryP	NFfrV3MyPiCq		MYPpcohq[mm2czD0c45q[yCETF7LJJR6em:\|aX7lJJBpd3OyaH;yfYxifGmxbh?=	MoGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyME[2PVYoRjF6MEC2Olk3RC:jPh?=
Wsu-NHL	MlTnSpVv[3Srb36gRZN{[Xl?	NWTvN29vPCEQvF2=	MofYNVYhcA>?		NXSzVYRocW6qaXLpeJMhfG:waXOgRmxPUyC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDByNk[5Okc,OThyME[2PVY9N2F-
LY18	NHTVdVdHfW6ldHnvckBCe3OjeR?=	MX20JO69VQ>?	NWj5[\|JIOTZiaB?=		M{PGb4lvcGmkaYTzJJRwdmmlIFLMUmshfHm{b4PpcoUheGixc4Doc5J6dGG2aX;u	NWLEbZZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwNFY3QTZpPkG4NFA3Pjl4PD;hQi=>
MV411	MX7GeY5kfGmxbjDhd5NigQ>?		Mm\IO\|IhcHK\|		NXPUUo13UW6qaXLpeIlwdiCxZjDGcJQ{KGmwIHj1cYFvKE2YNEGxJINmdGy\|IHHzd4V{e2WmIHHzJIF{e2W\|c3XkJIF{KHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGmwY4XiZZRqd25iYomgd5Bm[3S{b4Doc5RwdWW2comsJGVEPTB;MD6wNe69VS5?	NWP3ZplLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O\|k2OTRpPkK0O\|c6PTF2PD;hQi=>
TF1	MXfGeY5kfGmxbjDhd5NigQ>?		M2fneFEhcHJ?		M4O0TGlvcGmkaYTpc44hd2ZiSnHrNkBqdiCncon0bJJweG:rZYTpck1{fGmvdXzheIVlKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCjc4Pld5Nm\CCjczDwbI9{eGixLWP0ZZQ2KGGodHXyJFEhcHJiaX7jeYJifGmxbjygSWM2OD1yLkCxN:69VS5?	MlHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5N{m1NVQoRjJ2N{e5OVE1RC:jPh?=
neutrophils	MVTGeY5kfGmxbjDhd5NigQ>?				NHG1W4xKdmirYnn0bY9vKG:oIGPZT{BqdiCqdX3hckBv\XW2cn;wbIlteyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSoNmeHOrbH;uVlEwTmOpYX3tZXIudWWmaXH0[YQhe2mpbnHsbY5oKHKnc4DvcpNmeyxiRVO1NF0xNjB\|M988UU4>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ3N{KxN{c,OjJ{NUeyNVM9N2F-
SK-M-MC	MmHJSpVv[3Srb36gZZN{[Xl?		MYCxJIhz		M4jMVmlvcGmkaYTpc44hd2ZiUnX0JIlvKGi3bXHuJHNMNU1vTVOgZ4VtdHNiYYPz[ZN{\WRiYYOgZZN{\XO\|ZXSgZZMheGixc4Doc5J6dGG2aX;uJIFnfGW{IEGgbJIhcW6ldXLheIlwdixiRVO1NF0xNjB\|Nt88UU4>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd5OUWxOEc,OjR5N{m1NVQ9N2F-
mast cells	NXvKRmJITnWwY4Tpc44h[XO\|YYm=		M{OwT\|EhcHJ?		M1rOR2lvcGmkaYTpc44hd2ZiY1vpeEBqdiC\|dHXtJINmdGxiZnHjeI9zNXO2aX31cIF1\WRiYn;u[UBu[XK{b4eg[IVzcX[nZDDtc5V{\SCvYYP0JINmdGy\|IHHzd4V{e2WmIHHzJJBpd3OyaH;yfYxifGmxbjDh[pRmeiBzIHjyJIlv[3WkYYTpc44tKEWFNUC9NE4xPDcQvF2u	MkjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5N{m1NVQoRjJ2N{e5OVE1RC:jPh?=
B-cells	NV3pZ4hCTnWwY4Tpc44h[XO\|YYm=				NWXwcWRkUW6qaXLpeIlwdiCxZjDTXWshcW5iaIXtZY4hSi2lZXzsd{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRnPldJNqdG:wUkGvSoNo[W2vYWKtcYVlcWG2ZXSgd4lodmGuaX7nJJJme3CxboPld{whTUN3ME2wMlA1QM7:TT6=	NYXXWY86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyOVczOTNpPkKyNlU4OjF\|PD;hQi=>
Ramos	M3;uTmZ2dmO2aX;uJIF{e2G7				M3jnbmlvcGmkaYTpc44hd2ZiU4nrJIlvKGGwdHnoeY1idiCLZ12td5RqdXWuYYTl[EBpfW2jbjDSZY1weyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDCR3IudWWmaXH0[YQhSkyQSzDwbI9{eGixconsZZRqd25iYomgZ4VtdHWuYYKgZZN{[XluIFXDOVA:OC5yNUROwG0v	NUDzd49VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O\|k2OTRpPkK0O\|c6PTF2PD;hQi=>
mesangial cells	MY\GeY5kfGmxbjDhd5NigQ>?				NHrMOFBKdmirYnn0bY9vKG:oIGPZT{BqdiCldXz0eZJm\CCqdX3hckBu\XOjbnfpZYwh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIF\j[ZB{cWyxbmKxM2Zk\2GvbXHSMY1m\GmjdHXkJJNq\26jbHnu[{Bz\XOyb37z[ZMtKEWFNUC9NE4xPTcQvF2u	M4S3bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkW3NlE{Lz5{MkK1O\|IyOzxxYU6=
SK-N-SH	NYD2PIhtTnWwY4Tpc44h[XO\|YYm=				NYrGeVJwUW6qaXLpeIlwdiCxZjDS[ZQhcW5iaIXtZY4hW0tvTj3TTEBk\WyuczygSWM2OD1yLkC4{txONg>?	M4L3NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkW3NlE{Lz5{MkK1O\|IyOzxxYU6=
mouse bone marrow cells	MVnGeY5kfGmxbjDhd5NigQ>?				M37XcGlvcGmkaYTpc44hd2ZiSVyzJIRmeGWwZHXueEBxem:uaX\ldoF1cW:wIHnuJGM2Py:EMU[gcY92e2ViYn;u[UBu[XK{b4egZ4VtdHNidYPpcochYzOKXYTofY1q\GmwZTDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjF2N988UU4>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{NkiwOkc,OjR5Mk[4NFY9N2F-
B-cells	MmD3SpVv[3Srb36gZZN{[Xl?		NUjvR5VDOSCqch?=		MlnvTY5pcWKrdHnvckBw\iCVeXugbY4h[WyyaHHJ[20ue3SrbYXsZZRm\CCqdX3hckBDKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkAyKGi{IHnuZ5Vj[XSrb36gZpkh\myxdzDjfZRwdWW2comsJGVEPTB;MD6xOVHPxE1w	Mm\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5N{m1NVQoRjJ2N{e5OVE1RC:jPh?=
THP1	M2\3RmZ2dmO2aX;uJIF{e2G7				M2[zUWlvcGmkaYTpc44hd2ZiU2nLJIlvKGi3bXHuJHRJWDFiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGZk\XC\|aXzvcnIyN0[lZ3HtcYFTNW2nZHnheIVlKHOrZ37hcIlv\yC{ZYPwc45{\XNuIFXDOVA:OC5zN{JOwG0v	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ3N{KxN{c,OjJ{NUeyNVM9N2F-
B-cells	M13O[WZ2dmO2aX;uJIF{e2G7		NVuyTGJ6OSCqch?=		M1rodmlvcGmkaYTpc44hd2ZiU4nrJIlvKGGucHjhTYdONXO2aX31cIF1\WRiaIXtZY4hSiClZXzsd{Bie3Onc4Pl[EBieyCFREi2JIV5eHKnc4Ppc44h[W[2ZYKgNUBpeiCrbnP1ZoF1cW:wIHL5JIZtd3diY4n0c41mfHK7LDDFR\|UxRTBwM{O1{txONg>?	NXrVdWxxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O\|k2OTRpPkK0O\|c6PTF2PD;hQi=>
Ramos	MonJSpVv[3Srb36gZZN{[Xl?				MXLJcohq[mm2aX;uJI9nKFO7azDpckBidnSrIFnnUU1{fGmvdXzheIVlKGi3bXHuJHJidW:\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IFLMUmsheGixc4Doc5J6dGG2aX;uJIJ6KGOnbHz1cIFzKGG\|c3H5MEBKSzVyPUCuOFU4\|ryPLh?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{NkiwOkc,OjR5Mk[4NFY9N2F-
Rec1	MkHHSpVv[3Srb36gZZN{[Xl?	NX3vZ2xSOi53IIXN	NWm1b2NUPiCqcoO=		MmHuTY5pcWKrdHnvckBw\iCEVFugdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLlZ\|Eh[2WubIOgZZQhOi53IIXNJIlv[3WkYYTl[EBnd3JiNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCvZYToc4Q>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O\|c9N2F-
Rec1	MYTGeY5kfGmxbjDhd5NigQ>?	NH[5fokzNjVidV2=	M1fTdlYhcHK\|		MkX6TY5pcWKrdHnvckBw\iCVeXugdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLlZ\|Eh[2WubIOgZZQhOi53IIXNJIlv[3WkYYTl[EBnd3JiNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCvZYToc4Q>	NEnuO209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNlg4Pyd-MkWyNlI5Pzd:L3G+
Rec1	MWjGeY5kfGmxbjDhd5NigQ>?	NEjZSHIzNjVidV2=	M4G5WlYhcHK\|		MYfJcohq[mm2aX;uJI9nKEy7bjDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iUnXjNUBk\WyuczDheEAzNjVidV2gbY5kfWKjdHXkJIZweiB4IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKG2ndHjv[C=>	M3HyU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKyPFc4Lz5{NUKyNlg4PzxxYU6=
SJ-GBM2	NIfjTJNyUFSVIHHzd4F6				NXHqeHIxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	Mmj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	NYizcY9{eUiWUzDhd5NigQ>?				NVjDRVNQeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MV3xTHRUKGG\|c3H5				MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	MmjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	M3\BZZFJXFNiYYPzZZk>				M{DCW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	MYXxTHRUKGG\|c3H5				NVrYTm92eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	MofhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NVfPeoJ[eUiWUzDhd5NigQ>?				NGrlbJhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	M2n6XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NWXZfGlQeUiWUzDhd5NigQ>?				MmDUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	M13LcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-RPS6 / T-RPS6 / p-4E-BP1 / T-4E-BP1; PubMed: 23535559 Leukemia Four AML cell lines (a and b) were treated for 24 hours with vehicle versus R406. Western blots of (a) p-RPS6 (Ser240/244) and (b) p-4E-BP1 (Thr37/46). p-MEK / T-MEK / p-ERK / T-ERK; PubMed: 23535559 Leukemia AML cell lines were treated with vehicle versus R406. Western blots of p-MEK1/2 (Ser217/221) and p-ERK1/2 (Thr202/Tyr204) are depicted. p-c-RAF / T-c-RAF; PubMed: 23535559 Leukemia Effect of SYK inhibition on c-RAF in AML cells. AML cells were grown in the presence of 4 μM R406 for the indicated times and assessed for activation of c-RAF and ERK1/2. p-AKT / T-AKT / p-mTOR / T-mTOR; PubMed: 23535559 Leukemia Western blot of (a) p-AKT (Ser473) or (b) p-mTOR (Ser2448) in AML cell lines treated with R406 for 24 hours.	23535559
Growth inhibition assay	Cell viability (U87, U251 cells); PubMed: 31043589 Cell Death Dis U87 and U251 were insensitive to R406, with a calculated IC50 of more than 1 mM for both cell lines. Cell viability (GSC lines); PubMed: 31043589 Cell Death Dis Incubation with R406 significantly reduced the cell viability of both GSC lines, with an IC50 of 0.75 μM for GSC-1 and 0.89 μM for GSC-2 respectively.	31043589

体内研究

在已经预防处理的鼠内进行阳性Arthus 反应，5 mg/kg R406诱导鼠皮肤病变达到86%。R406作用于抗体诱导的关节炎鼠模型，也有效抑制炎症。^[1] 自身免疫反应时，R406不会影响巨噬细胞和嗜中性粒细胞的功能，免疫毒性为最低水平。^[3]

动物实验：^[1]	- 合并 Animal Models: 在C57BL/6鼠中腹腔注射150 μL 取自成年K/BxN鼠的混合血清诱导产生关节炎。 Dosages: 1 或5 mg/kg Administration: 口服处理 (Only for Reference)

参考文献

[4] Zhu Y, et al. Toxicol Appl Pharmacol, 2007, 221(3), 268-277.

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL (159.07 mM)
	Water	Insoluble
	Ethanol	0 mg/mL (0.0 mM)
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%dmso+95%cornoil	6mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download R406 SDF

分子量	628.63
化学式	C₂₂H₂₃FN₆O₅.C₆H₆O₃S
CAS号	841290-81-1
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01725230	Completed	Drug: Fostamatinib\|Drug: Rosuvastatin\|Drug: Simvastatin	Rheumatoid Arthritis	AstraZeneca	November 2012	Phase 1
NCT01598571	Completed	Drug: Fostamatinib	Healthy	AstraZeneca	May 2012	Phase 1
NCT01387308	Completed	Drug: Fostamatinib	Healthy	AstraZeneca	August 2011	Phase 1
NCT01355354	Completed	Drug: Digoxin\|Drug: Fostamatinib	Healthy Volunteers\|Rheumatoid Arthritis	AstraZeneca	June 2011	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What’s the difference between S1533 and S2194?
回答：
S1533 and S2194 are two different forms of R406. S1533 is the free base form, containing only R406 molecule without a acid added to it. S2194 has an additional C6H6O3S acid on it which makes the molecule a salt form. The free base and salt forms have same biology activities. Free base has a lower molecular weight and salt form has a better solubility in DMSO.

Syk Signaling Pathway Map

Syk Inhibitors with Unique Features

活性最高的Syk抑制剂

PRT062607 (P505-15, BIIB057) HCl : Syk, IC50=1 nM.
用于临床的Syk抑制剂

Fostamatinib (R788) : Phase III for Rheumatoid Arthritis.
最新的Syk抑制剂

PRT062607 (P505-15, BIIB057) HCl : Novel, highly selective Syk inhibitor with IC50 of 1 nM, >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.
经典的Syk抑制剂

R406 (free base) : Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 2.

研究领域

产品类型

定制您的化合物库

R406

客户使用Selleck生产的R406发表文献76篇：

产品安全说明书

Syk抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download R406 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

常见问题及建议解决方法

Syk Signaling Pathway Map

Syk Inhibitors with Unique Features

相关Syk产品